Using Digital Twins to Decrease Enrollment and Increase Statistical Power in Alzheimer's Disease Trials (CTAD 2020)

Background: Drug development for Alzheimer’s disease (AD) is increasingly expensive and time-consuming.  To decrease the high failure rate of these trials, it will be necessary to improve clinical trial design by reducing total trial size and/or recruitment time.  Randomized controlled trials (RCTs) have long been the gold-standard among clinical trial designs, even though they can be very inefficient. The volume of clinical trials provides an opportunity to improve the efficiency of AD trials, which has been highlighted by the FDA in a number of communications. With data collected from the control groups of many prior AD trials and state-of-the-art statistical methods, we have developed machine learning (ML) technology to comprehensively model the progression of control subjects. Our model can generate digital twins, which are digital subject records generated from the baseline data of actual subjects in a trial. These digital twins show the potential outcomes of individual subjects had they received a placebo.


Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Press

Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Blog

Welcoming Dr. Taylor to Unlearn.AI’s Board of Directors

Press

Unlearn Appoints AstraZeneca’s Chief Medical Officer Ann E. Taylor, M.D. to Board of Directors

Ann E. Taylor, M.D., Chief Medical Officer at AstraZeneca, has joined the Unlearn Board of Directors.
I’m honored to have such an inspirational and experienced leader like Dr. Taylor join our board.
The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.